These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8124835)

  • 21. Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
    Kass DA; Van Anden E; Becker LC; Kasper EK; White WB; Feldman AM
    Am J Cardiol; 1996 Sep; 78(6):652-6. PubMed ID: 8831399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of apoptosis in human choriocarcinoma cell lines by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone).
    Isaka K; Fujito A; Sagawa Y; Yudate T; Nishi H; Ito H; Takayama M
    Oncol Rep; 2002; 9(6):1299-305. PubMed ID: 12375038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of vesnarinone on nitric oxide synthesis in rat cardiac myocytes.
    Kurosaki K; Ikeda U; Maeda Y; Shimpo M; Ueno S; Shimada K
    Cardiovasc Res; 1998 Apr; 38(1):192-7. PubMed ID: 9683921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of vesnarinone on cardiac function in patients with severe congestive heart failure.
    Scherrer-Crosbie M; Cocca-Spofford D; DiSalvo TG; Semigran MJ; Dec GW; Picard MH
    Am Heart J; 1998 Nov; 136(5):769-77. PubMed ID: 9812070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Inotropic effect of novel domestic cardiotonic agent, vesnarinone--test in vitro].
    Han W; Qin Y; Zhang Z; Zhou S; Yang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1994 Sep; 25(3):316-20. PubMed ID: 7896252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
    Furusawa S; Ohashi Y; Asanoi H
    J Clin Pharmacol; 1996 May; 36(5):477-81. PubMed ID: 8739027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of vesnarinone in the progression of myocardial damage in experimental autoimmune myocarditis in rats.
    Ishiyama S; Hiroe M; Nishikawa T; Shimojo T; Hosokawa T; Ikeda I; Toyozaki T; Kasajima T; Marumo F
    Cardiovasc Res; 1999 Aug; 43(2):389-97. PubMed ID: 10536669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
    Cohn JN; Goldstein SO; Greenberg BH; Lorell BH; Bourge RC; Jaski BE; Gottlieb SO; McGrew F; DeMets DL; White BG
    N Engl J Med; 1998 Dec; 339(25):1810-6. PubMed ID: 9854116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury.
    Lazarus DD; Kambayashi T; Yato-Kioka M; Baumann H; Jacob CO; Strassmann G
    Int J Immunopharmacol; 1997 Jan; 19(1):49-58. PubMed ID: 9226479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart.
    Kitakaze M; Minamino T; Funaya H; Node K; Shinozaki Y; Mori H; Hori M
    Circulation; 1997 Apr; 95(8):2108-14. PubMed ID: 9133521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of vesnarinone on the bone marrow stromal cell-dependent proliferation and differentiation of HL60 cells in vitro.
    Nabeshima R; Aizawa S; Nakano M; Toyama K; Sugimoto K; Kaidow A; Imai T; Handa H
    Exp Hematol; 1997 Jun; 25(6):509-15. PubMed ID: 9197329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vesnarinone suppresses TNF-induced activation of NF-kappa B, c-Jun kinase, and apoptosis.
    Manna SK; Aggarwal BB
    J Immunol; 2000 Jun; 164(11):5815-25. PubMed ID: 10820260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vesnarinone inhibits adenosine uptake in endothelial cells, smooth muscle cells and myocytes, and mediates cytoprotection.
    Kitakaze M; Fong M; Yoshitake M; Minamino T; Node K; Okuyama Y; Terada N; Kambayashi T; Hori M
    J Mol Cell Cardiol; 1997 Dec; 29(12):3413-7. PubMed ID: 9441846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts.
    Ross JS; Goldfine SM; Herrold EM; Borer JS
    Am J Ther; 1998 Nov; 5(6):369-75. PubMed ID: 10099079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effect of gamma-hydroxybutyrate (GHB) on proinflammatory cytokine gene expression in coronary surgical procedures].
    Kleinschmidt S; Bauer M; Wanner G; Bussmann D; Ziegenfuss T; Menger MD; Larsen R
    Anaesthesist; 1998 Aug; 47(8):651-62. PubMed ID: 9770088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure.
    Conraads VM; Bosmans JM; Schuerwegh AJ; Goovaerts I; De Clerck LS; Stevens WJ; Bridts CH; Vrints CJ
    J Heart Lung Transplant; 2005 Jul; 24(7):854-9. PubMed ID: 15982613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
    Harada K; Supriatno ; Yoshida H; Sato M
    Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
    Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
    Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
    Matsui S; Matsumori A; Matoba Y; Uchida A; Sasayama S
    J Clin Invest; 1994 Sep; 94(3):1212-7. PubMed ID: 8083362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
    Soran O; Young JD; Holubkov R; Loftus S; Bourge R; Carson P; Jaski B; White BG; Feldman AM
    J Card Fail; 1999 Sep; 5(3):195-200; discussion 201-2. PubMed ID: 10496192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.